Contact PR

To use this feature, join Babbler easily !

arrow_back

Babbler is a free tool for journalists
Do not suffer news anymore, control it


By signing up you will be able to contact hundreds of press officer :
Caroline Grangie
Leboncoin
Media relation manager
Manon Guignard
Uber
Communication Associate
Sheherazade Renoux
PMU
Communication Manager

To learn more, watch the video

You're 1 click away from signing up
What is Babbler!

Previous

Nice to see you again !

Press release

Toujeo® reduced risk of severe low blood sugar compared to insulin glargine
timer minutes reading time minute reading time

Copy link
toujeo-r-reduced-risk-of-severe-low-blood-sugar-compared-to-insulin-glargine

Click to get original image size

VIENNA - February 14, 2018 - With the continued evolution in diabetes care and a growing understanding of today’s insulin options, Sanofi is pleased to share new real-world evidence results which showed that Toujeo® (insulin glargine 300 Units/mL) significantly reduced the risk of severe low blood sugar (hypoglycemia) events compared to the long-acting insulins, insulin glargine 100 Units/mL (Lantus) and insulin detemir. These data are being presented at the 11th Annual Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Vienna, Austria.


Hit the download button to get the document.

  • Health & Medicine
  • Medicine
  • Men's Health
  • Women's Health
inscrit avec succès

Congratulations, you're registered on Babbler!

Discover now all the news waiting for you on Babbler: visit your newsfeed.!

Your topics have been selected, you can change it by clicking here

  • Health & Medicine
  • Medicine
  • Men's Health